Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2009
  • Online publication date: May 2010

Chapter 4 - Cerebral amyloid angiopathy

References

1. Divry P. Etude histochimique des plaques seniles. J Belge Neurol Psychiatr 1927; 27: 643–657.
2. Fischer O. Die presbyophrene Demenz deren anatomische Grundlage und klinische Abgrenzung. Z. Gesamte Neurol Psychiatr 1909; 3: 371–471.
3. Oppenheim G. Uber drusige Nekrosen in der Grosshirnrinde. Neurol Centralbl 1909; 28: 410–413.
4. Surbek B. L'angiopathie dyshorique (Morel) de l'ecorce cerebrale. Acta Neuropathol 1961; 1: 168–197.
5. Jellinger K. Cerebrovascular amyloidosis with cerebral hemorrhage. J Neurol 1977; 214: 195–206.
6. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979; 54: 22–31.
7. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311–324.
8. Kase CS. Cerebral amyloid angiopathy. In: Kase CS, Caplan LR, eds. Intracerebral Hemorrhage. Boston, Butterworth-Heinemann. 1994; 179–200.
9. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000; 20: 8–22.
10. Herzig MC, Winkler DT, Walker LC, Jucker M. Transgenic mouse models of cerebral amyloid angiopathy. Adv Exp Med Biol 2001; 487: 123–128.
11. Van Nostrand WE, Melchor JP, Romanov G, Zeigler K, Davis J. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann N Y Acad Sci 2002; 977: 258–265.
12. Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 2002; 13: 48–52.
13. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813–836.
14. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448–452.
15. Rensink AA, de Waal RM, Kremer B, Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 2003; 43: 207–223.
16. Love S. Contribution of cerebral amyloid angiopathy to Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1–4.
17. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998; 153: 725–733.
18. Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 1986; 45: 79–90.
19. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30: 637–649.
20. Yamada M, Itoh Y, Shintaku M, et al. Immune reactions associated with cerebral amyloid angiopathy. Stroke 1996; 27: 1155–1162.
21. Maat-Schieman ML, van Duinen SG, Rozemuller AJ, Haan J, Roos RA. Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 273–284.
22. Uchihara T, Akiyama H, Kondo H, Ikeda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-beta protein in Alzheimer's disease brain. Stroke 1997; 28: 1948–1950.
23. Vinters HV, Natte R, Maat-Schieman ML, et al. Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). Acta Neuropathol 1998; 95: 235–244.
24. Maeda A, Yamada M, Itoh Y, et al. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 1993; 24: 1857–1864.
25. Natte R, Vinters HV, Maat-Schieman ML, et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke. 1998; 29: 1588–1594.
26. McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 1999; 58: 711–718.
27. Shinkai Y, Yoshimura M, Ito Y, et al. Amyloid ß-proteins 1–40 and 1–42(43) in the soluble fraction of extra- and intracranial blood vessels. Ann Neurol 1995; 38: 421–428.
28. Natte R, Yamaguchi H, Maat-Schieman ML, et al. Ultrastructural evidence of early non-fibrillar Abeta42 in the capillary basement membrane of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type. Acta Neuropathol 1999; 98: 577–582.
29. McGowan E, Pickford F, Kim J, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005; 47: 191–199.
30. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45–53.
31. Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to beta-amyloid(1–42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994; 667: 138–142.
32. Gravina SA, Ho LB, Eckman CB, et al. Amyloid beta protein (A-beta) in Alzheimers disease brain – biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995; 270: 7013–7016.
33. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 1995; 37: 294–299.
34. Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid ß-peptides and Apolipoprotein E in Down syndrome. Implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16–32.
35. Castano EM, Prelli F, Soto C, et al. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. J Biol Chem 1996; 271: 32185–32191.
36. Mann DM, Iwatsubo T, Ihara Y, et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996; 148: 1257–1266.
37. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Progression of cerebral amyloid angiopathy. Accumulation of amyloid-ß40 in already affected vessels. J Neuropathol Exp Neurol 1998; 57: 353–359.
38. Snow AD, Mar H, Nochlin D, et al. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am J Pathol 1990; 137: 1253–1270.
39. Vinters HV, Nishimura GS, Secor DL, Pardridge WM. Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. Am J Pathol 1990; 137: 233–240.
40. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163–166.
41. Kalaria RN, Kroon SN. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem Biophys Res Commun 1992; 186: 461–466.
42. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 11282–11286.
43. Verbeek MM, Eikelenboom P, de Waal RM. Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 751–761.
44. Cho HS, Hyman BT, Greenberg SM, Rebeck GW. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 2001; 60: 342–349.
45. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 1999; 96: 14088–14093.
46. Van Dorpe J, Smeijers L, Dewachter I, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol 2000; 157: 1283–1298.
47. Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 2001; 158: 1065–1071.
48. Winkler DT, Bondolfi L, Herzig MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 2001; 21: 1619–1627.
49. Fryer JD, Taylor JW, DeMattos RB, et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci 2003; 23: 7889–7896.
50. Herzig MC, Winkler DT, Burgermeister P, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7: 954–960.
51. Miao J, Xu F, Davis J, et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol 2005; 167: 505–515.
52. Domnitz SB, Robbins EM, Hoang AW, et al. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J Neuropathol Exp Neurol 2005; 64: 588–594.
53. Robbins EM, Betensky RA, Domnitz SB, et al. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci 2006; 26(2): 365–371.
54. Van Broeckhoven C, Haan J, Bakker E, et al. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990; 248: 1120–1122.
55. Levy E, Carman MD, Fernandez Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248: 1124–1126.
56. Grabowski TJ, Cho HS, Vonsattel JPG, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001; 49: 697–705.
57. Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 2004; 279: 20296–20306.
58. Fryer JD, Simmons K, Parsadanian M, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005; 25: 2803–2810.
59. Wyss-Coray T, Lin C, Yan F, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001; 7: 612–618.
60. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-ß1 in transgenic mice and in Alzheimer's disease. Nature 1997; 389: 603–606.
61. Kimchi EY, Kajdasz S, Bacskai BJ, Hyman BT. Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy. J Neuropathol Exp Neurol 2001; 60: 274–279.
62. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1–40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000; 20: 1659–1668.
63. Niwa K, Younkin L, Ebeling C, et al. Abeta 1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 2000; 97: 9735–9740.
64. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168–171.
65. Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV. Toxicity of dutch (E22Q) and flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke 2000; 31: 534–538.
66. Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 1998; 70: 216–223.
67. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J Biol Chem 2001; 276: 32860–32866.
68. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE. Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of Dutch-type mutant. J Neurosci Res 2000; 60: 804–810.
69. Beckmann N, Schuler A, Mueggler T, et al. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci 2003; 23: 8453–8459.
70. Park L, Anrather J, Forster C, et al. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 2004; 24: 334–342.
71. Lee JM, Yin KJ, Hsin I, et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 2003; 54: 379–382.
72. Rosenberg GA, Sullivan N, Esiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001; 32: 1162–1168.
73. Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995; 1: 138–142.
74. Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999; 38: 11570–11576.
75. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston Criteria. Neurology 2001; 56: 537–539.
76. Tomonaga M. Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 1981; 29: 151–157.
77. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983; 14: 924–928.
78. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke 1988; 19: 205–210.
79. Greenberg SM, Vonsattel J-PG. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997; 28: 1418–1422.
80. Lee SS, Stemmermann GN. Congophilic angiopathy and cerebral hemorrhage. Arch Pathol Lab Med 1978; 102: 317–321.
81. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993; 116: 135–141.
82. Greenberg SM. Cerebral amyloid angiopathy. In: Mohr JP, Choi D, Grotta JC, et al., eds. Stroke: Pathophysiology, Diagnosis and Management, 4th edn. New York, Harcourt, Inc. 2004; 693–705.
83. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46: 1592–1596.
84. Hanyu H, Tanaka Y, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer's disease. J Neurol 2003; 250: 1496–1497.
85. Atri A, Locascio JJ, Lin JM, et al. Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neuro degenerative Dis 2005; 2: 305–312.
86. Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E e4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996; 27: 1333–1337.
87. Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004; 63: 1606–1612.
88. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 9649–9653.
89. Fisher CM. Pathological observations in hypertensive cerebral hemorrhage. J Neuropathol Exp Neurol 1971; 30: 536–550.
90. Bahemuka M. Primary intracerebral hemorrhage and heart weight: a clinicopathologic case-control review of 218 patients. Stroke 1987; 18: 531–536.
91. Massaro AR, Sacco RL, Mohr JP, et al. Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology 1991; 41: 1881–1885.
92. Schutz H, Bodeker RH, Damian M, Krack P, Dorndorf W. Age-related spontaneous intracerebral hematoma in a German community. Stroke 1990; 21: 1412–1418.
93. Broderick J, Brott T, Tomsick T, Leach A. Lobar hemorrhage in the elderly. The undiminishing importance of hypertension. Stroke 1993; 24: 49–51.
94. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998; 31: 1223–1229.
95. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002; 33: 1190–1196.
96. Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein e gene with lobar intracerebral hemorrhage. Stroke 2005; 36: 1874–1879.
97. Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982; 13: 62–73.
98. Iso H, Jacobs DJ, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial [see comments]. N Engl J Med 1989; 320: 904–910.
99. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989; 20: 1460–1465.
100. Gatchev O, Rastam L, Lindberg G, et al. Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women. Ann Epidemiol 1993; 3: 403–409.
101. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309: 11–15. Erratum in: BMJ 1994; 309(6969): 1619.
102. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? Stroke 1996; 27: 1993–1998.
103. Giroud M, Creisson E, Fayolle H, et al. Risk factors for primary cerebral hemorrhage: a population-based study–the Stroke Registry of Dijon. Neuroepidemiology 1995; 14: 20–26.
104. Segal AZ, Chiu RI, Eggleston-Sexton PM, Beiser A, Greenberg SM. Low cholesterol as a risk factor for primary intracerebral hemorrhage: a case-control study. Neuroepidemiology 1999; 18: 185–193.
105. Revesz T, Holton JL, Lashley T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002; 12: 343–357.
106. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992; 1: 218–221.
107. Cras P, van Harskamp F, Hendriks L, et al. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala–>Gly mutation. Acta Neuropathol 1998; 96: 253–260.
108. Tagliavini F, Rossi G, Padovani A, et al. A new ßPP mutation related to hereditary cerebral haemorrhage. Alzheimers Rep 1999; 2: S28.
109. Miravalle L, Tokuda T, Chiarle R, et al. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000; 275: 27110–27116.
110. Obici L, Demarchi A, de Rosa G, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58: 639–644.
111. Selkoe DJ. The origins of Alzheimer disease. A is for amyloid. JAMA 2000; 283: 1615–1617.
112. Greenberg SM, Shin Y, Grabowski TJ, et al. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 2003; 60: 1020–1022.
113. Brooks WS, Kwok JB, Halliday GM, et al. Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology 2004; 63: 1613–1617.
114. Palsdottir A, Abrahamson M, Thorsteinsson L, et al. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 1988; 2: 603–604.
115. Levy E, Lobez-Otin C, Ghiso J, Geltner D, Frangione B. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. J Exp Med 1989; 169: 1771–1778.
116. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999; 399: 776–781.
117. Vidal R, Revesz T, Rostagno A, et al. A decamer duplication in the 3′ region of the BRI gene originates an amyloid peptide that is associated with dementia in a danish kindred. Proc Natl Acad Sci U S A 2000; 97: 4920–4925.
118. Vidal R, Garzuly F, Budka H, et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 1996; 148: 361–366.
119. Herrick MK, DeBruyne K, Horoupian DS, et al. Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996; 47: 988–992.
120. Petersen RB, Goren H, Cohen M, et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol 1997; 41: 307–313.
121. Mascalchi M, Salvi F, Pirini MG, et al. Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology 1999; 53: 1498–1503.
122. Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999; 122: 183–190.
123. Jin K, Sato S, Takahashi T, et al. Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. J Neurol Neurosurg Psychiatry 2004; 75: 1463–1466.
124. Greenberg SM, Rebeck GW, Vonsattel JPV, Gomez-Isla T, Hyman BT. Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38: 254–259.
125. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996; 148: 2083–2095.
126. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996; 47: 190–196.
127. Zarow C, Zaias B, Lyness SA, Chui H. Cerebral amyloid angiopathy in Alzheimer disease is associated with apolipoprotein E4 and cortical neuron loss. Alzheimer Dis Assoc Disord 1999; 13: 1–8.
128. Walker LC, Pahnke J, Madauss M, et al. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly Acta Neuropathol 2000; 100: 36–42.
129. Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50: 961–965.
130. McCarron MO, Nicoll JAR. Apolipoprotein E genotype in relation to sporadic and Alzheimer-related CAA. In: Verbeek MM, de Waal MW, Vinters HV, eds. Cerebral Amyloid Angiopathy in Alzheimer's Disease and Related Disorders. Dordrecht, Kluwer Academic Publishers. 2000; 81–102.
131. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342: 240–245.
132. Yamada M, Sodeyama N, Itoh Y, et al. Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly. Stroke 1997; 28: 2219–2221.
133. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001; 158: 2165–2175.
134. Yamada M. Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci 2004; 226: 41–44.
135. Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005; 58: 459–462.
136. Tian J, Shi J, Bailey K, Mann DM. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease. Neuropathol Appl Neurobiol 2004; 30: 46–56.
137. Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. Stroke 1983; 14: 915–923.
138. Yamada M, Itoh Y, Otomo E, Hayakawa M, Miyatake T. Subarachnoid haemorrhage in the elderly: a necropsy study of the association with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 1993; 56: 543–547.
139. Miller JH, Wardlaw JM, Lammie GA. Intracerebral haemorrhage and cerebral amyloid angiopathy: CT features with pathological correlation. Clin Radiol 1999; 54: 422–429.
140. Ohshima T, Endo T, Nukui H, et al. Cerebral amyloid angiopathy as a cause of subarachnoid hemorrhage. Stroke 1990; 21: 480–483.
141. Kase CS. Lobar hemorrhage. In: Kase CS, Caplan LR, eds. Intracerebral Hemorrhage. Boston, Butterworth-Heinemann. 1994; 363–382.
142. Atlas SW, Mark AS, Grossman RI, Gomori JM. Intracranial hemorrhage: gradient-echo MR imaging at 1.5 T. Comparison with spin-echo imaging and clinical applications. Radiology 1988; 168: 803–807.
143. Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996; 46: 1751–1754.
144. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*- weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999; 20: 637–642.
145. Tsushima Y, Tamura T, Unno Y, Kusano S, Endo K. Multifocal low-signal brain lesions on T2*-weighted gradient-echo imaging. Neuroradiology 2000; 42: 499–504.
146. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471–1477.
147. Ramsay DA, Penswick JL, Robertson DM. Fatal streptokinase-induced intracerebral haemorrhage in cerebral amyloid angiopathy. Can J Neurol Sci 1990; 17: 336–341.
148. Leblanc R, Haddad G, Robitaille Y. Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis. Neurosurgery 1992; 31: 586–590.
149. Wijdicks EF, Jack CRJ. Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction. Stroke 1993; 24: 554–557.
150. Melo TP, Bogousslavsky J, Regli F, Janzer R. Fatal hemorrhage during anticoagulation of cardioembolic infarction: role of cerebral amyloid angiopathy. Eur Neurol 1993; 33: 9–12.
151. Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45: 649–658.
152. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55: 947–951.
153. Anderson JL, Karagounis L, Allen A, et al. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991; 68: 166–170.
154. De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992; 19: 289–294.
155. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897–902.
156. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156: 409–416.
157. Bornebroek M, Haan J, van Buchem MA, et al. White matter lesions and cognitive deterioration in presymptomatic carriers of the amyloid precursor protein gene codon 693 mutation. Arch Neurol 1996; 53: 43–48.
158. Mead S, James-Galton M, Revesz T, et al. Familial British dementia with amyloid angiopathy: early clinical, neuropsychological and imaging findings. Brain 2000; 123: 975–986.
159. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993; 43: 2073–2079.
160. Silbert PL, Bartleson JD, Miller GM, et al. Cortical petechial hemorrhage, leukoencephalopathy, and subacute dementia associated with seizures due to cerebral amyloid angiopathy. Mayo Clin Proc 1995; 70: 477–480.
161. Natte R, Maat-Schieman ML, Haan J, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001; 50: 765–772.
162. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35: 2616–2619.
163. Greenberg SM. Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis 2002; 13: 42–47.
164. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169–175.
165. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58: 1629–1634.
166. Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985; 18: 54–59.
167. Gurol ME, Irizarry MC, Smith EE, et al. Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66(1): 23–29.
168. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy – a histopathological assessment. Dement Geriatr Cogn Disord 2002; 14: 161–166.
169. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical Manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004; 55: 246–252.
170. Gray F, Vinters HV, Le Noan H, et al. Cerebral amyloid angiopathy and granulomatous angiitis: immunohistochemical study using antibodies to the Alzheimer A4 peptide. Hum Pathol 1990; 21: 1290–1293.
171. Mandybur TI, Balko G. Cerebral amyloid angiopathy with granulomatous angiitis ameliorated by steroid-cytoxan treatment. Clin Neuropharmacol 1992; 15: 241–247.
172. Fountain NB, Eberhard DA. Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Neurology 1996; 46: 190–197.
173. Caplan LR, Louis DN. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10–2000. A 63-year-old man with changes in behavior and ataxia. N Engl J Med 2000; 342: 957–965.
174. Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128: 500–515.
175. Fountain NB, Lopes MB. Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone. Neurology 1999; 52: 660–662.
176. Smith DB, Hitchcock M, Philpott PJ. Cerebral amyloid angiopathy presenting as transient ischemic attacks. Case report. J Neurosurg 1985; 63: 963–964.
177. Yong WH, Robert ME, Secor DL, Kleikamp TJ, Vinters HV. Cerebral hemorrhage with biopsy-proved amyloid angiopathy. Arch Neurol 1992; 49: 51–58.
178. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880–884.
179. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059–1064.
180. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001; 56: 773–777.
181. Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006; 66(2): 206–209.
182. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004; 35: 1415–1420.
183. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34: 1710–1716.
184. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1–5.
185. Greene GM, Godersky JC, Biller J, Hart MN, Adams HPJ. Surgical experience with cerebral amyloid angiopathy. Stroke 1990; 21: 1545–1549.
186. Leblanc R, Preul M, Robitaille Y, Villemure JG, Pokrupa R. Surgical considerations in cerebral amyloid angiopathy. Neurosurgery 1991; 29: 712–718.
187. Matkovic Z, Davis S, Gonzales M, Kalnins R, Masters CL. Surgical risk of hemorrhage in cerebral amyloid angiopathy. Stroke 1991; 22: 456–461.
188. Minakawa T, Takeuchi S, Sasaki O, et al. Surgical experience with massive lobar haemorrhage caused by cerebral amyloid angiopathy. Acta Neurochir (Wien) 1995; 132: 48–52.
189. Izumihara A, Ishihara T, Iwamoto N, Yamashita K, Ito H. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999; 30: 29–33.
190. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905–915.
191. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143–148.
192. Greenberg SM, Rosand J, Schneider AT, et al. A phase II study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 2006; 20: 269–274.
193. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399: A23–31.
194. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ß(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489–1499.
195. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333–344.
196. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285–3290.
197. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 2002; 70: 493–500.
198. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003; 9: 453–457.
199. Weller RO. Drainage pathways of CSF and interstitial fluid. In: Kalimo H, ed. Pathology and Genetics. Cerebrovascular Diseases. Basel, ISN Neuropath Press. 2005; 50–55.
200. Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 2003; 29: 106–117.
201. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99–102.